歐洲蛋白質體學市場：按細分市場、應用和國家分類的分析和預測（2025-2035 年）

歐洲蛋白質體學市場概覽：

歐洲蛋白質體學市場預計將從2024年的69.1億美元成長到2035年的243.6億美元，年複合成長率（CAGR）為12.25%。高解析度質譜和次世代定序技術的進步擴大蛋白質體學在歐洲的應用，實現更深入、更精確的蛋白質分析。該地區對個人化醫療的日益重視進一步推動了市場需求，這主要得益於對發現新的生物標記和改進疾病譜分析的不懈努力。歐盟的大力研究經費、公私合營以及醫院、生技公司和學術機構之間的策略聯盟促進新型蛋白質體學應用的快速發展。歐洲人口老化和慢性病的盛行率上升，促使人們更需要改善診斷和早期檢測技術。這些因素共同推動蛋白質體學成為臨床創新的基礎組成部分，並成為該地區生命科學研究生態系統的關鍵驅動力。

市場區隔:

細分 1：依服務類別

• 樣品製備
• 蛋白質體學技術
  • 試劑和耗材
  • 裝置
  • 軟體
• 蛋白質體學服務

細分 2：依應用

• 生物標記的發現與檢驗
• 蛋白質體分析和圖譜繪製
• 藥物發現與開發
• 伴隨診斷
• 蛋白質-蛋白質相互作用

細分3：依地區

• 歐洲

歐洲蛋白質體學市場趨勢、促進因素與挑戰：

趨勢：

• 從發現性蛋白質體學到臨床和轉化應用的轉變加速，尤其是在腫瘤學和神經病學領域。
• 快速採用先進的質譜、單細胞蛋白質體學和高通量蛋白質分析平台
• 拓展基於蛋白質體學的診斷方法和伴隨生物標記的開發，以支持精準醫療。
• 加強大學、醫院、生物技術公司和歐盟資助的研究網路之間的合作
• 人們對整合基因組學、轉錄組學和蛋白質組學的多體學工作流程的興趣日益濃厚

促進因素：

• 歐盟資助的強力計畫和國家研究津貼將加速蛋白質體學創新
• 對早期檢測工具、疾病分層和個人化治療方案的需求很高
• 先進的醫療基礎設施和數位健康解決方案的廣泛應用
• 生技公司、製藥公司和合約研究組織（CRO）加強對生物標記發現和治療開發的研發投入
• 更加重視標準化、品管和檢驗的臨床蛋白質體學流程

課題：

• 嚴格的法律規範，包括遵守體外診斷醫療器材法規（IVDR），會增加成本並延長產品上市時間。
• 歐洲多個地區缺乏熟練的蛋白質體學專家和生物資訊學家
• 精密設備的昂貴成本及其維護費用限制了其在小規模研究實驗室的應用。
• 整合跨多體學平台和醫療保健系統的片段化資料
• 基於蛋白質體學的診斷技術的商業化進程緩慢，且有償付障礙。

本報告調查歐洲蛋白質體學市場，並總結了關鍵趨勢、市場影響因素分析、法律制度、技術和專利分析、市場規模趨勢和預測、按各個細分市場、地區/主要國家進行的詳細分析、競爭格局以及主要企業的概況。

目錄

執行摘要

範圍和定義

第1章 市場：產業展望

• 市場概覽與生態系統
• 與其他體學相比，蛋白質體學的比較優勢和劣勢
• 供應鏈分析
• 市場動態
  • 趨勢、促進因素、挑戰和機會：評估當前和未來的影響
• 趨勢
  • 加速端到端蛋白質體學工作流程的自動化
  • 拓展蛋白質體學研究以識別疾病生物標記
  • 公司間的眾多合作
• 市場動態
  • 市場促進因素
  • 市場挑戰
  • 商業策略
  • 企業策略
  • 市場機會
• 監管狀態/合規性
  • 歐洲
• 專利分析
  • 專利分析（依年份）
  • 專利分析（依國家）

第2章 區域

• 區域摘要
• 歐洲
  • 區域概覽
  • 市場成長促進因素
  • 市場問題
  • 依供應類別
  • 依用途
  • 依國家/地區

第3章 市場：競爭基準化分析與公司概況

• 公司簡介
  • DiaSorin SPA

第4章 調查方法

This report can be delivered in 2 working days.

Introduction to Europe Proteomics Market

The Europe proteomics market is projected to reach $24.36 billion by 2035 from $6.91 billion in 2024, growing at a CAGR of 12.25% during the forecast period 2025-2035. Advances in high-resolution mass spectrometry and next-generation sequencing technologies are increasing proteomics usage in Europe, allowing for deeper and more precise protein analysis. Demand is being further increased by the region's increasing emphasis on personalized healthcare, which is being fueled by initiatives to find new biomarkers and improve disease-profiling skills. The development of new proteomic applications is developing quickly thanks to strong EU-backed research funding, public-private partnerships, and strategic alliances between hospitals, biotech companies, and academic institutions. Improved diagnostics and early-detection technologies are becoming more and more necessary as Europe's population ages and the prevalence of chronic illnesses rises. When taken as a whole, these factors are establishing proteomics as a fundamental component of clinical innovation and a major force behind the ecosystem of life-science research in the area.

Market Introduction

Advances in high-resolution mass spectrometry and next-generation sequencing technologies are increasing proteomics usage in Europe, allowing for deeper and more precise protein analysis. Demand is being further increased by the region's increasing emphasis on personalized healthcare, which is being fueled by initiatives to find new biomarkers and improve disease-profiling skills. The development of new proteomic applications is developing quickly thanks to strong EU-backed research funding, public-private partnerships, and strategic alliances between hospitals, biotech companies, and academic institutions. Improved diagnostics and early-detection technologies are becoming more and more necessary as Europe's population ages and the prevalence of chronic illnesses rises. When taken as a whole, these factors are establishing proteomics as a fundamental component of clinical innovation and a major force behind the ecosystem of life-science research in the area.

Across the region, the push toward personalised healthcare is accelerating the adoption of proteomics in oncology, neurology, cardiology, and chronic disease management. The development of next-generation proteomic applications is being accelerated by national innovation awards, EU-funded research initiatives, and cross-border partnerships between hospitals, biotech firms, academic institutions, and CROs. This robust financing ecosystem promotes standardization, data interoperability, and clinical validation of proteomic procedures in addition to supporting scientific innovation.

The need for early detection techniques, predictive biomarkers, and more focused treatment approaches is growing as Europe's population ages and the prevalence of chronic diseases rises. Proteomics is therefore becoming recognized as a key facilitator of better patient outcomes and healthcare effectiveness. Europe is well-positioned to spearhead the next generation of clinical and technological developments in proteomics thanks to its strong infrastructure, quality-focused regulations, and developed research environment.

Market Segmentation:

Segmentation 1: By Offering

• Sample Preparation
• Proteomics Technologies
  • Reagents and Consumables
  • Instruments
  • Software
• Proteomics Services

Segmentation 2: By Application

• Biomarker Discovery and Validation
• Proteome Profiling and Mapping
• Drug Discovery and Development
• Companion Diagnostics
• Protein-Protein Interactions

Segmentation 3: By Region

• Europe

Europe Proteomics Market Trends, Drivers and Challenges

Trends

• Growing shift from discovery proteomics to clinical and translational applications, especially in oncology and neurology.
• Rapid adoption of advanced mass spectrometry, single-cell proteomics, and high-throughput protein analysis platforms.
• Expansion of proteomics-based diagnostics and companion biomarker development supporting precision medicine.
• Increasing collaborations among universities, hospitals, biotech firms, and EU-funded research networks.
• Rising focus on integrated multi-omics workflows combining genomics, transcriptomics, and proteomics.

Drivers

• Strong EU funding programs and national research grants accelerating proteomics innovation.
• High demand for early-detection tools, disease stratification, and personalized treatment pathways.
• Advanced healthcare infrastructure and widespread adoption of digital health solutions.
• Growing R&D investment from biotech, pharma, and CROs in biomarker discovery and therapeutic development.
• Increased emphasis on standardization, quality control, and validated clinical proteomics pipelines.

Challenges

• Stringent regulatory frameworks, including IVDR compliance, increasing cost and time to market.
• Shortage of skilled proteomics experts and bioinformaticians across several European regions.
• High cost of advanced instrumentation and maintenance, limiting adoption in smaller labs.
• Fragmented data integration across multi-omics platforms and healthcare systems.
• Slow commercialization and reimbursement barriers for proteomics-based diagnostics.

How can this report add value to an organization?

Product/Innovation: This report enables organizations to identify high-value opportunities in the Europe proteomics market. It guides R&D investment strategies, technology adoption, and pipeline optimization, helping companies prioritize initiatives that accelerate biomarker discovery, disease diagnostics, and therapeutic development. By highlighting emerging technologies, strategic collaborations, and platform scalability, this report helps organizations strengthen their competitive positioning and capitalize on the rapid expansion of proteomics across research, clinical, and pharmaceutical applications.

Growth/Marketing: The report delivers in-depth insights into regional adoption trends, emerging markets, and partnership opportunities, supporting strategic market entry and commercialization planning. It enables companies to identify growth potential across offering, technology, application, and end-user segments. By understanding regional R&D investments, regulatory frameworks, and technology adoption rates, organizations can refine marketing, licensing, and collaboration strategies, maximize visibility, and increase return on investment in a competitive global landscape.

Competitive: This report provides comprehensive company profiling, competitive benchmarking, highlighting strategic collaborations, funding activities, mergers, acquisitions, and technology adoption trends. Stakeholders gain a clear understanding of competitor focus areas, R&D priorities, and market positioning. This intelligence allows organizations to identify gaps, anticipate market shifts, and formulate strategies to differentiate themselves, optimize market entry, and maintain leadership in the proteomics ecosystem.

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

• 1.1 Market Overview and Ecosystem
• 1.2 Comparative Advantages and Disadvantages of Proteomics Over Other Omics
• 1.3 Supply Chain Analysis
• 1.4 Market Dynamics
  • 1.4.1 Trends, Drivers, Challenges, and Opportunities: Current and Future Impact Assessment, 2024-2035
• 1.5 Trends
  • 1.5.1 Increasing Automation for End-to-End Proteomics Workflow
  • 1.5.2 Growing Proteomics Research to Identify Disease Biomarkers
  • 1.5.3 Significant Number of Collaborations among Market Players
• 1.6 Market Dynamics
  • 1.6.1 Market Drivers
    • 1.6.1.1 Rising Prevalence of Chronic Diseases
    • 1.6.1.2 Continuous Technological Advancements
    • 1.6.1.3 Increasing Demand for Personalized Medicine
  • 1.6.2 Market Challenges
    • 1.6.2.1 High Costs of Acquisition Hindering the Adoption of Proteomics Technologies
    • 1.6.2.2 Shortage of Skilled Professionals
  • 1.6.3 Business Strategies
    • 1.6.3.1 Key Product Launch/Expansion
  • 1.6.4 Corporate Strategies
    • 1.6.4.1 Key Partnerships
    • 1.6.4.2 Key Funding and Grants
    • 1.6.4.3 Key Merger and Acquisitions
  • 1.6.5 Market Opportunities
    • 1.6.5.1 Expanding Proteomics Market in Emerging Regions through Affordable Technologies
• 1.7 Regulatory Landscape/Compliance
  • 1.7.1 Europe
    • 1.7.1.1 Regulatory Requirements for Proteomics Products Intended as Medical Devices
      • 1.7.1.1.1 EU Medical Device Regulation
      • 1.7.1.1.2 EU In Vitro Diagnostic Regulation
      • 1.7.1.1.3 Regulatory Requirements for Clinical Proteomics Labs in the EU
• 1.8 Patent Analysis
  • 1.8.1 Patent Analysis (by Year)
  • 1.8.2 Patent Analysis (by Country)

2 Region

• 2.1 Regional Summary
• 2.2 Europe
  • 2.2.1 Regional Overview
  • 2.2.2 Driving Factors for Market Growth
  • 2.2.3 Factors Challenging the Market
  • 2.2.4 By Offering
    • 2.2.4.1 By Proteomics Technologies
  • 2.2.5 By Application
  • 2.2.6 By Country
    • 2.2.6.1 U.K.
      • 2.2.6.1.1 By Offering
      • 2.2.6.1.2 By Application
    • 2.2.6.2 Germany
      • 2.2.6.2.1 By Offering
      • 2.2.6.2.2 By Application
    • 2.2.6.3 France
      • 2.2.6.3.1 By Offering
      • 2.2.6.3.2 By Application
    • 2.2.6.4 Italy
      • 2.2.6.4.1 By Offering
      • 2.2.6.4.2 By Application
    • 2.2.6.5 Spain
      • 2.2.6.5.1 By Offering
      • 2.2.6.5.2 By Application
    • 2.2.6.6 Rest-of-Europe
      • 2.2.6.6.1 By Offering
      • 2.2.6.6.2 By Application

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Company Profile
  • 3.1.1 DiaSorin S.P.A.
    • 3.1.1.1 Overview
    • 3.1.1.2 Top Products/Product Portfolio
    • 3.1.1.3 Top Competitors
    • 3.1.1.4 Target Customers
    • 3.1.1.5 Key Personal
    • 3.1.1.6 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Europe Proteomics Market (by Scenario), $Billion, 2024, 2030, and 2035
• Figure 2: Proteomics Market, $Billion, 2024 and 2035
• Figure 3: Europe Proteomics Market (by Offering), $Billion, 2024, 2030, and 2035
• Figure 4: Europe Proteomics Market (by Application), $Billion, 2024, 2030, and 2035
• Figure 5: Europe Proteomics Market Segmentation
• Figure 6: Ecosystem Europe Proteomics Market
• Figure 7: Supply Chain and Risks within the Supply Chain
• Figure 8: Proteomics Market, Patent Analysis (by Year), January 2021-December 2024
• Figure 9: Proteomics Market, Patent Analysis (by Country), January 2021-December 2024
• Figure 10: U.K. Proteomics Market, $Billion, 2024-2035
• Figure 11: Germany Proteomics Market, $Billion, 2024-2035
• Figure 12: France Proteomics Market, $Billion, 2024-2035
• Figure 13: Italy Proteomics Market, $Billion, 2024-2035
• Figure 14: Spain Proteomics Market, $Billion, 2024-2035
• Figure 15: Rest-of-Europe Proteomics Market, $Billion, 2024-2035
• Figure 16: Data Triangulation
• Figure 17: Top-Down and Bottom-Up Approach
• Figure 18: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Opportunities across Regions
• Table 3: Partnerships and Collaborations in the Europe Proteomics Market
• Table 4: Proteomics Market (by Region), $Billion, 2024-2035
• Table 5: Europe Proteomics Market (by Offering), $Billion, 2024-2035
• Table 6: Europe Proteomics Market (by Proteomics Technologies), $Billion, 2024-2035
• Table 7: Europe Proteomics Market (by Application), $Billion, 2024-2035
• Table 8: U.K. Proteomics Market (by Offering), $Billion, 2024-2035
• Table 9: U.K. Proteomics Market (by Proteomics Technologies), $Billion, 2024-2035
• Table 10: U.K. Proteomics Market (by Application), $Billion, 2024-2035
• Table 11: Germany Proteomics Market (by Offering), $Billion, 2024-2035
• Table 12: Germany Proteomics Market (by Proteomics Technologies), $Billion, 2024-2035
• Table 13: Germany Proteomics Market (by Application), $Billion, 2024-2035
• Table 14: France Proteomics Market (by Offering), $Billion, 2024-2035
• Table 15: France Proteomics Market (by Proteomics Technologies), $Billion, 2024-2035
• Table 16: France Proteomics Market (by Application), $Billion, 2024-2035
• Table 17: Italy Proteomics Market (by Offering), $Billion, 2024-2035
• Table 18: Italy Proteomics Market (by Proteomics Technologies), $Billion, 2024-2035
• Table 19: Italy Proteomics Market (by Application), $Billion, 2024-2035
• Table 20: Spain Proteomics Market (by Offering), $Billion, 2024-2035
• Table 21: Spain Proteomics Market (by Proteomics Technologies), $Billion, 2024-2035
• Table 22: Spain Proteomics Market (by Application), $Billion, 2024-2035
• Table 23: Rest-of-Europe Proteomics Market (by Offering), $Billion, 2024-2035
• Table 24: Rest-of-Europe Proteomics Market (by Proteomics Technologies), $Billion, 2024-2035
• Table 25: Rest-of-Europe Proteomics Market (by Application), $Billion, 2024-2035